This observational study will assess the efficacy and safety of MabThera/Rituxan (Rituximab) in patients with active rheumatoid arthritis who have had an inadequate response or are intolerant to anti-TNF therapy. Data will be collected from patients initiated on MabThera/Rituxan therapy according to standard of care in routine clinical practice. For each patient data will be collected for 92 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01196780?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
